ArticleCell death & disease2025
Disrupted bone microenvironment and immune recovery following total body irradiation in a murine model.
Article in Cell death & disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Irradiation is an effective therapy for eliminating cancer cells and serves as a critical preparative regimen for hematopoietic stem cell transplantation (HSCT). However, irradiation affects healthy tissue, disrupting bone tissue and bone marrow homeostasis, which leads to skeletal and immune dysfunction. To investigate these effects, we used a female murine model to explore the mechanisms underlying the skeletal damage caused by total body irradiation. Experiments were carried out over a 12-week period of total body irradiation and HSCT, supplemented by an acute study involving only total body irradiation and osteoclastogenesis. Irradiation resulted in a depletion of bone marrow immune cells, followed by an increase in bone marrow cellularity 12 weeks after irradiation and HSCT compared to naive controls, indicating late-stage local immune induction. Cortical and trabecular bone loss appeared 2 weeks post-irradiation and HSCT and persisted throughout the study. This bone damage was accompanied by a sustained increase in apoptotic cells in the bone marrow within 6 h post-irradiation and persisted for up to 12 weeks after irradiation and HSCT. This was coupled with elevated local expression of the pro-apoptotic Bax gene and an increase in TGF-β1, a gene associated with the clearance of apoptotic cells. In vitro studies demonstrated that macrophages and pre-osteoclasts, but not fully differentiated osteoclasts, efficiently cleared apoptotic cells, resulting in increased levels of TGF-β1 in the culture supernatant. While the clearance of apoptotic cells and associated TGF-β1 signaling were evident, their direct role in skeletal outcomes remains unclear. These findings suggest that persistent apoptotic cells contribute to impaired bone remodeling, potentially affecting osteoclast function and the bone microenvironment. Additional research is needed to investigate whether targeting apoptotic cell clearance can mitigate bone damage and promote skeletal recovery following irradiation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.